Table 6 Information on G. lucidum for the treatment of GI cancer
From: A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer
Cancer | G. lucidum | Cell type | Effects | Target/Mechanisms | Refs. |
|---|---|---|---|---|---|
ESCC | G. lucidum spore powder | KYSE140 KYSE510 | Anti-proliferation, anti-metastasis | PI3K/AKT/mTOR, Erk signaling pathways | [96] |
ESCC | GA-D | EC9706 Eca109 | Anti-proliferation, pro-apoptosis, pro-autophagy | mTOR signal transduction pathway | [38] |
GC | GLP | MKN28 NCI-N87 AGS | Anti-proliferation, pro-apoptosis | Bcl-2/pro-caspase-3 cleaved-PARP/LC3-II/p62 | [14] |
GC | Cotreatment of GLE and QCT | SNU719 MKN1-EBV | Pro-apoptosis, anti-viral | Bcl-2/caspase 3/CYCS/EBV | [97] |
GC | MGL | AGS | Anti-cancer | LC3-II/p62 | [98] |
GC | MGL | AGS | Anti-autophagy | LC3-II | [99] |
GC | EGL | AGS | Pro-apoptosis | AKT signal pathway | [100] |
GC | EGL | AGS | Anti-invasion | MMP-2/MMP-9 | [101] |
CCA | Supercritical-CO2 extract of G. lucidum spores | TFK-1 | Anti-migration | Epithelial-mesenchymal transition | [102] |
Hepatoma | Supercritical fluid extract of G. lucidum | BEL-7402 | Anti-proliferation, pro-apoptosis | Blocking cell cycle | [103] |
Hepatoma | GA | BEL7402 | Anti-proliferation | Blocking cell cycle | [27] |
HCC | GLP, ginsenoside Rg3, and oridonin | Huh7 HepG2 | Pro-immune regulation, anti-proliferation | p-EGFR and AKT/GSK3 signaling pathways | [104] |
HCC | GLP | SK-HEP-1 Huh-7 | Anti-proliferation, anti-migration | PI3K/AKT signaling pathway | [105] |
HCC | GLSP | SW1116 | Pro-apoptosis | Regulating the PI3K/AKT signaling pathway | [106] |
HCC | GL-PP | Huh7 | Anti-migration, pro-apoptosis | No data | [107] |
HCC | GLP | HepG2 | Anti-proliferation, anti-migration | VEGF | [108] |
HCC | GA-A | HepG2 SMMC7721 | Anti-metastasis | Cyclin D1/p21/cleaved caspase 3 | [29] |
HCC | LAB | HepG2 | Anti-invasion | ERK1/2/AP-1/ NF-κB /MMP-9 | [54] |
HCC | GLE | HepG2 | Anti-proliferation, anti-metastasis | ERK1/2/c-Jun/c-Fos/AKT/MMP-2/MMP-9 | [109] |
Colon cancer | AGA | SW620 SW480 HT29 | Anti-proliferation, anti-migration | P21/p53-dependent and independent manner | [110] |
Colon cancer | EGLP | HCT116 | Pro-apoptosis | Bax/p-ERK/cleaved caspase-3/Bcl-2/p-AKT1/COX-2 | [75] |
Colon cancer | GLT | HT-29 | Pro-autophagy | Beclin-1/LC-3/p38 MAPK | [111] |
CRC | WGL | HCT116 | Anti-proliferation, pro-apoptosis | Cyclin A/B1/p21/p27 | [70] |
CRC | GLE | HCT116 | Anti-proliferation, pro-apoptosis, pro-autophagy | Bcl-2/Bax/cleaved caspase-3/PARP | [112] |
CRC | GA-Me | HCT116 | Anti-proliferation, pro-apoptosis | AKT signal pathway | [41] |
CRC | GLP | HCT116 | Anti-proliferation, anti-migration, pro-apoptosis | caspase-8/Fas/caspase-3 | [73] |
CRC | EGL | HCT116 | Anti-migration | E-cadherin/MMP-1/ MMP-2 | [113] |
CRC | GLP | LoVo | Anti-migration, pro-apoptosis | Fas/caspase-3/PARP | [114] |
CRC | GLP | HT-29 HCT116 | Pro-apoptosis | MAPK/ERK signaling pathway | [71] |
CRC | GLR | HT29 HCT116 | Anti-proliferative, anti-colony formation | ERK1/2/AP-1/NF-κB /MMP-9 | [77] |